Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian and triple negative breast cancers.
Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.
Etablissement d'origine : Chimie ParisTech - PSL, SU, CNRS
Fondateur : Gérard Jaouen
CEO : Franck Pradier
Directeur : Professeur G. Jaouen